Problems with the variants or quasi-species of the Hepatitis B virus (HBV) in treatment
1 Research Unit Service. Río Hortega University Hospital. Valladolid. Spain.
2 Clinical Analysis Service. Río Hortega University Hospital. International University of La Rioja (UNIR). Spain
Review Article
Magna Scientia Advanced Biology and Pharmacy, 2021, 03(01), 013-018
Article DOI: 10.30574/msabp.2021.3.1.0029
Publication history:
Received on 07 June 2021; revised on 09 July 2021; accepted on 11 July 2021
Abstract:
The HBV genome has a very high mutation rate, which is why it is considered a highly variable virus, being able to produce different variants or quasi-species in the same host, differentiated by small mutations that favor the oncogenic potential of the virus, in addition to attenuating the immunogenicity and antigenicity.
There are a large number of epidemiological findings and studies that suggest a relationship between genotypes and pre-core / core variants of the hepatitis B virus with the clinical course of infection and the response to different antiviral treatments.
Keywords:
Hepatitis B; HBV; Virus; Mutations; Variants; Quasi-species
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0